Medicus Pharma Receives FDA Approval To Proceed With Phase 2b Clinical Study Of SkinJect 200 Mcg To Treat Patients With Gorlin Syndrome Presenting With Multiple Basal Cell Carcinomas
Share
Why It Matters
Medicus Pharma got permission from the FDA to test its medicine SkinJect on more patients with a rare skin cancer condition. This is a normal step forward in medicine testing, so watch if the company keeps hitting its testing goals on schedule.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.